西藏易明西雅医药科技股份有限公司 关于续聘 2025 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"和"本公司"）于 2025年4月23日召开的第三届董事会审计委员会第十二次会议、第三届董事会第 二十三次会议和第三届监事会第二十一次会议，审议通过了《关于公司<续聘2025 年会计师事务所>的议案》，公司董事会同意续聘立信会计师事务所（特殊普通 合伙）（以下简称"立信会计师事务所"或"立信"）为公司2025年度财务报告 审计机构和内部控制审计机构。关于续聘会计师事务所的议案尚需提交2024年年 度股东大会审议。现将相关事项公告如下： 一、拟聘任会计师事务所的基本信息 证券代码：002826 证券简称：易明医药 公告编号：2025-017 （一）机构信息 1、基本信息 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计 ...

西藏易明西雅医药科技股份有限公司 审计委员会对会计师事务所2024年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》和《公司章程》等规定 和要求，西藏易明西雅医药科技股份有限公司（以下简称"公司"）董事会审计 委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会 计师事务所 2024 年度履职评估及履行监督职责的情况报告如下 一、2024年年审会计师事务所基本情况 （一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网 络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、期货业务 许可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB）注 册登记。 截至 2024 年末，立信拥有合伙人 29 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥148,531,481.16, a decrease of 7.41% compared to ¥160,425,522.45 in the same period last year[4]. - Net profit attributable to shareholders was ¥18,793,851.93, down 32.64% from ¥27,899,079.55 year-on-year[4]. - The basic earnings per share decreased by 33.33% to ¥0.10 from ¥0.15 in the same period last year[5]. - Net profit for the period was CNY 18,928,556.57, down 32.5% from CNY 28,050,728.06 in the previous period[27]. - The net profit attributable to the parent company was 18,793,851.93, a decrease from 27,899,079.55, representing a decline of approximately 32.7% year-over-year[28]. - The total comprehensive income attributable to the parent company was 18,727,675.15, down from 27,944,608.45, indicating a decrease of about 32.9% compared to the previous period[28]. Cash Flow and Operating Activities - Cash flow from operating activities decreased by 42.56% to ¥30,865,875.72 from ¥53,738,523.14 in the same period last year[10]. - Net cash flow from operating activities decreased by 42.56% year-on-year, primarily due to a decrease of CNY 18.185 million in special industrial support funds received[11]. - Cash inflows from operating activities totaled 190,986,029.02, compared to 202,042,040.04 in the previous period, showing a decrease of approximately 5.5%[29]. - The net cash flow from operating activities was 30,865,875.72, down from 53,738,523.14, representing a decline of about 42.6% year-over-year[30]. - The company received cash from sales of goods and services amounting to 178,926,631.19, an increase from 170,015,189.63, reflecting a growth of about 5.3%[29]. - The company paid 38,337,179.15 in cash for goods and services, down from 41,711,034.09, indicating a decrease of approximately 8.5%[30]. - The company reported a cash outflow of 79,324,691.65 for other operating activities, which increased from 60,947,936.52, representing a rise of about 30.0%[30]. Assets and Liabilities - The company's total assets increased by 6.48% to ¥986,510,989.35 from ¥926,469,234.87 at the end of the previous year[5]. - Total assets increased to CNY 986,510,989.35 from CNY 926,469,234.87, representing a growth of 6.5%[24]. - Total liabilities rose to CNY 218,975,807.44 from CNY 180,892,906.43, an increase of 21.1%[25]. - The company's equity attributable to shareholders increased to CNY 760,827,826.19 from CNY 739,003,677.36, a rise of 2.9%[25]. Research and Development - Research and development expenses rose by 342.13% to ¥1,197,352.52 from ¥270,814.38 year-on-year[10]. - R&D expenses increased by CNY 926,500 compared to the same period last year, primarily due to increased investment in research and development[11]. - Research and development expenses increased to CNY 1,197,352.52 from CNY 270,814.38, a significant increase of 341.5%[27]. Financial Management and Investments - The company reported a significant increase in short-term borrowings by 54.69%, amounting to ¥35,300,443.10 compared to ¥22,819,445.17 previously[9]. - The company received government subsidies amounting to ¥10,223,089.90, primarily related to industry support funds[7]. - Financial expenses increased by CNY 592,900 compared to the same period last year, mainly due to a decrease in interest income from current deposits[11]. - Investment income increased by CNY 228,100 compared to the same period last year, mainly due to increased income from financial product investments[11]. - The company has entrusted CNY 20 million in financial management, with all funds remaining unexpired[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,855[13]. - The largest shareholder, Gao Fan, holds 25.59% of the shares, totaling 48,800,382 shares[13]. - The company completed the first grant registration of the 2024 restricted stock incentive plan, granting 3.44 million shares at a price of CNY 6.45 per share[16].

证券代码：002826 股票简称：易明医药 公告编号：2025-026 西藏易明西雅医药科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"本公司"或"公司"）第 三届董事会第二十三次会议审议通过了《关于召开 2024 年年度股东大会的议案》， 定于 2025 年 5 月 16 日（星期五）下午 14:00 召开 2024 年年度股东大会，现将 本次会议的相关事项通知如下： 一、本次会议召开的基本情况 （一）会议届次：2024 年年度股东大会 （二）会议召集人：公司董事会 （三）会议召开的合法、合规性：公司第三届董事会第二十三次会议审议通 过相关议案，本次股东大会会议的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》等的规定。 （四）会议表决方式：现场记名书面投票与网络投票相结合 （五）会议时间： 1、现场会议时间为：2025 年 5 月 16 日（星期五）下午 14:00。 2、网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 5 月 16 日上午 9 ...

Financial Performance - The company's operating revenue for 2024 was CNY 651,883,906.60, a decrease of 2.27% compared to CNY 667,038,998.92 in 2023[17] - Net profit attributable to shareholders for 2024 reached CNY 45,928,802.86, representing a significant increase of 198.50% from CNY 15,386,479.71 in 2023[17] - The net profit after deducting non-recurring gains and losses was CNY 18,446,708.96, up 1,579.33% from CNY 1,098,456.92 in the previous year[17] - The net cash flow from operating activities was CNY 111,572,566.21, down 33.14% from CNY 166,880,943.95 in 2023[17] - Basic earnings per share for 2024 were CNY 0.25, an increase of 212.50% compared to CNY 0.08 in 2023[17] - Total assets at the end of 2024 were CNY 926,469,234.87, a slight decrease of 0.14% from CNY 927,743,602.85 at the end of 2023[17] - Net assets attributable to shareholders decreased by 0.81% to CNY 739,003,677.36 from CNY 745,017,765.57 in 2023[17] - The weighted average return on net assets for 2024 was 6.26%, an increase of 4.19% from 2.07% in 2023[17] Revenue and Profit Trends - The company's total revenue for Q1 was approximately ¥160.43 million, with a decline to ¥139.04 million in Q4, reflecting a decrease of about 13.4% quarter-over-quarter[21] - Net profit attributable to shareholders decreased significantly from ¥27.90 million in Q1 to ¥4.11 million in Q4, indicating a decline of approximately 85.3%[21] - Cardiovascular product revenue decreased by 55.61% to ¥84,210,323.29, while diabetes product revenue increased by 41.17% to ¥474,057,188.28[56] Cash Flow and Investments - The cash flow from operating activities showed volatility, with a net cash inflow of ¥67.71 million in Q3, but a net outflow of ¥2.26 million in Q4[21] - Investment cash inflow increased by 15.24% to ¥521,239,418.32, while investment cash outflow rose by 1.40% to ¥502,242,767.81, leading to a net cash flow from investment activities of ¥18,996,650.51, a significant turnaround from a negative cash flow in the previous year[77] - Financing cash inflow surged by 107.27% to ¥22,799,206.96, while financing cash outflow decreased by 4.61% to ¥67,062,215.78, resulting in a net cash flow from financing activities of -¥44,263,008.82, an improvement of 25.36% compared to the previous year[78] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1 per 10 shares to all shareholders, based on a total of 186,913,950 shares[3] - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares (including tax), with a total cash dividend amounting to RMB 18,691,395.00[153] - The cash dividend distribution accounts for 100% of the total profit distribution amount[153] Market Position and Product Development - The core product, Miglitol tablets (Aotianping®), holds the largest market share in China's Miglitol formulation market, with successful bids in 25 provinces as of the reporting period[38] - The company has developed a diverse business model, including self-produced drugs, third-party cooperative drugs, raw materials, and drug promotion services[38] - The company’s self-produced drugs are all included in the 2024 National Medical Insurance Directory, indicating strong market competitiveness and growth potential[44] - The company is committed to continuous innovation and development in the pharmaceutical sector, focusing on chronic disease treatments and gynecological core products[37] Research and Development - R&D expenses rose by 12.92% to ¥15,482,858.58, indicating a focus on innovation and product development[69] - The number of R&D personnel increased by 14.63% from 41 in 2023 to 47 in 2024, with the proportion of R&D staff rising from 9.34% to 11.66%[75] - R&D investment amounted to ¥15,982,858.58 in 2024, representing a 32.36% increase from ¥12,075,151.59 in 2023, with R&D investment as a percentage of operating revenue rising from 1.81% to 2.45%[75] Compliance and Governance - The company has maintained compliance with industry regulations, enhancing its operational integrity and market competitiveness[33] - The company is enhancing its governance structure and management level to ensure effective operation as its scale increases[99] - The company operates independently from its controlling shareholders in terms of business, finance, personnel, and assets, ensuring no major related party transactions[117] Environmental Responsibility - The company has been recognized as an environmentally friendly enterprise by the Sichuan Provincial Department of Ecology and Environment, maintaining compliance with environmental regulations[52] - The company has invested a total of 712,700 yuan in environmental governance and protection in 2024, including an environmental protection tax of 290 yuan[170] - The company has established an environmental self-monitoring plan for 2024, including quarterly and monthly monitoring of wastewater and air emissions[169] Employee and Management Structure - The total number of employees at the end of the reporting period is 403, with 135 in production, 98 in sales, and 54 in technical roles[148] - The company has implemented a performance-based salary system that includes basic salary, performance salary, and benefits[149] - The company has conducted various training programs for employees, including management training and new employee onboarding[152] Investor Relations and Transparency - The company is actively engaging with investors through various communication channels to enhance transparency and information sharing[110] - The company has established a talent strategy, focusing on employee rights and providing various training opportunities for continuous growth[172] - The company has maintained a strong commitment to information disclosure, ensuring timely and accurate updates on its financial status and major events[174]

证券代码：002826 股票简称：易明医药 公告编号：2025-019 西藏易明西雅医药科技股份有限公司 一、本次授权概述 关于提请股东大会授权董事会办理以简易程序向特定对象发行股 票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第三届董事会第二十三次会议和第三届监事会第二十一次会议，审议通过了《关于提请股 东大会授权董事会办理以简易程序向特定对象发行股票的议案》。 根据《上市公司证券发行注册管理办法》《深圳证券交易所上市公司证券发行上市审 核规则》《深圳证券交易所上市公司证券发行与承销业务实施细则》等相关规定，公司董 事会提请股东大会授权董事会以简易程序向特定对象发行融资总额不超过人民币三亿元 且不超过最近一年末净资产百分之二十的股票，授权期限自公司 2024 年年度股东大会审 议通过之日起至公司 2025 年年度股东大会召开之日止。本议案尚需提交公司 2024 年年度 股东大会审议。现将有关情况公告如下： 二、本次授权具体内容 1、确认公司是否符合以简易程序向特定对象发行股票的条 ...

Core Viewpoint - Yiming Pharmaceutical (002826) has shown a slight increase in stock price and received a significant government subsidy, which is expected to positively impact its financial performance in 2025 [1][2]. Company Stock Performance - As of March 28, 2025, Yiming Pharmaceutical's stock closed at 11.01 yuan, up 0.18% from the previous week, with a weekly high of 11.18 yuan and a low of 10.25 yuan [1]. - The company's current total market capitalization is 2.124 billion yuan, ranking 143rd out of 152 in the chemical pharmaceutical sector and 4736th out of 5140 in the A-share market [1]. Shareholder Changes - On April 1, 2025, the company's board approved the reduction of 94,000 shares, representing 0.0493% of the total share capital, during which the stock price increased by 3.62% [1][2]. Government Subsidy Announcement - Yiming Pharmaceutical received a government subsidy of 10 million yuan from the Lhasa Economic and Technological Development Zone Management Committee, which accounts for 64.99% of the company's audited net profit attributable to shareholders for 2023 [1]. - This subsidy is expected to increase the company's total profit for 2025 by 10 million yuan, subject to the final audit results [1][2].

证券代码：002826 证券简称：易明医药 公告编号：2025-012 西藏易明西雅医药科技股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）近日收到西藏 拉萨经济技术开发区管理委员会拨付的2024年度产业扶持专项资金 10,000,000.00元，占公司2023年度经审计归属于上市公司股东净利润的 64.99%。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相 关的政府补助，是指除与资产相关的政府补助之外的政府补助。 公司本次获得的政府补助属于与收益相关的政府补助。 2、补助的确认、计量 计结果为准。 3、补助对上市公司的影响 上述政府补助预计将增加公司2025年度利润总额10,000,000.00元，最终影 响以年度审计机构审计结果为准。 4、风险提示和其他说明 本次收到的产业扶持专项资金为部分金额，最终金额 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-011 西藏易明西雅医药科技股份有限公司 关于公司董事、持有 5%以上股东减持股份的预披露公告 董事、持有 5%以上股东周战先生和董事许可先生保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有西藏易明西雅医药科技股份有限公司（以下简称"公司"）股份 14,361,702 股（占公司总股本比例的 7.5319%，占剔除公司回购专用账户股份后 总股本比例的 7.6836%）的董事、持股 5%以上股东周战先生，计划自本公告披露 之日起 15 个交易日后的 3 个月内，以集中竞价方式或大宗交易方式减持公司股 份不超过 3,590,000 股（不超过公司总股本比例的 1.8828%，不超过剔除公司回 购专用账户股份后总股本比例的 1.9207%）。 持有公司股份 1,215,447 股（占公司总股本的 0.6374%，占剔除公司回购专 用账户股份后总股本比例的 0.6503%）的董事许可先生，计划自本公告披露之日 起 15 个交易日后的 3 ...

证券代码：002826 股票简称：易明医药 公告编号：2025-010 西藏易明西雅医药科技股份有限公司 关于控股股东部分股份提前解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）近日接到控股股 东、实际控制人高帆先生的通知，获悉高帆先生其质押的股份提前办理了解除质 押手续，具体事项如下： | 股东 | 是否为控股股 东或第一大股 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总股 本比例 | 起始日 | | 解除日期 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一致行 | （股） | （%） | （%） | | | | | | | | 动人 | | | | | | | | | | 高帆 | 是 | 2,450,000 | 5.02 | 1.28 | 年 2024 | 月 6 | 年 2025 2 | 月 | 华西证券股 | | | | | | | 17 日 | ...